Related references
Note: Only part of the references are listed.The use of methotrexate in dermatology: a review
Sarah Shen et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2012)
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan et al.
IMMUNOLOGY AND CELL BIOLOGY (2012)
Cutaneous T cell lymphoma: update on treatment
Uwe Wollina
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Monitoring the spatiotemporal dynamics of proteins at replication forks and in assembled chromatin using isolation of proteins on nascent DNA
Bianca M. Sirbu et al.
NATURE PROTOCOLS (2012)
Histone Deacetylase Inhibitors Globally Enhance H3/H4 Tail Acetylation Without Affecting H3 Lysine 56 Acetylation
Paul Drogaris et al.
SCIENTIFIC REPORTS (2012)
Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management
Ryan A. Wilcox
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Analysis of protein dynamics at active, stalled, and collapsed replication forks
Bianca M. Sirbu et al.
GENES & DEVELOPMENT (2011)
HDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation
Susan C. McQuown et al.
JOURNAL OF NEUROSCIENCE (2011)
Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability
Srividya Bhaskara et al.
CANCER CELL (2010)
Inhibition of Histone Deacetylase in Cancer Cells Slows Down Replication Forks, Activates Dormant Origins, and Induces DNA Damage
Chiara Conti et al.
CANCER RESEARCH (2010)
Epigenetic therapy of lymphoma using histone deacetylase inhibitors
Maribel Cotto et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma
Frederick Lansigan et al.
DRUGS (2010)
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Teppei Yamaguchi et al.
GENES & DEVELOPMENT (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse Model
Myriam Rai et al.
PLOS ONE (2010)
The impact of heterochromatin on DSB repair
Aaron A. Goodarzi et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2009)
Bexarotene therapy for mycosis fungoides and Sezary syndrome
R. A. Abbott et al.
BRITISH JOURNAL OF DERMATOLOGY (2009)
Chemical Probes Identify a Role for Histone Deacetylase 3 in Friedreich's Ataxia Gene Silencing
Chunping Xu et al.
CHEMISTRY & BIOLOGY (2009)
Clinical Studies of Histone Deacetylase Inhibitors
H. Miles Prince et al.
CLINICAL CANCER RESEARCH (2009)
Analysis of re-replication from deregulated origin licensing by DNA fiber spreading
Elizabeth S. Dorn et al.
NUCLEIC ACIDS RESEARCH (2009)
Liver-specific deletion of histone deacetylase 3 disrupts metabolic transcriptional networks
Sarah K. Knutson et al.
EMBO JOURNAL (2008)
Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
C. James Chou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control
Srividya Bhaskara et al.
MOLECULAR CELL (2008)
Histone deacetylase inhibitors: molecular mechanisms of action
W. S. Xu et al.
ONCOGENE (2007)
Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
CLINICAL CANCER RESEARCH (2007)
FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma
Bhupinder S. Mann et al.
ONCOLOGIST (2007)
Towards a proteome-scale map of the human protein-protein interaction network
JF Rual et al.
NATURE (2005)
Histone deacetylase inhibitors: insights into mechanisms of lethality
RR Rosato et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Mechanisms of selective anticancer action of histone deacetylase inhibitors
A Insinga et al.
CELL CYCLE (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
WD dipeptide motifs and LXXLL motif of chicken HIRA are necessary for transcription repression and the latter motif is essential for interaction with histone deacetylase-2 in vivo
A Ahmad et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Histone deacetylases as therapeutic targets in hematologic malignancies
A Melnick et al.
CURRENT OPINION IN HEMATOLOGY (2002)
Functional domains of histone deacetylase-3
WM Yang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Histone deacetylase as a new target for cancer chemotherapy
M Yoshida et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Genomewide studies of histone deacetylase function in yeast
BE Bernstein et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
